Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | KRAS | P01116 | 4/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | WNT1 | P04628 | 2/20 | 0.31 |
| ▸ | GSK3B | P49841 | 2/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30869399 | 1.00 | ESR1 (0.36) | ESR1ESR2KRASKCNH2MCHR1 | |
| SCHEMBL30869501 | 0.92 | ESR1 (0.35) | ESR1ESR2KRASKCNH2MCHR1 | |
| SCHEMBL30869401 | 0.89 | ESR1 (0.33) | ESR1ESR2KRASKCNH2MCHR1 | |
| SCHEMBL30869601 | 0.89 | ESR1 (0.33) | ESR1ESR2KRASKCNH2MCHR1 | |
| SCHEMBL30869651 | 0.88 | ESR1 (0.32) | ESR1ESR2 | |
| SCHEMBL30869579 | 0.88 | ESR1 (0.32) | ESR1ESR2 | |
| SCHEMBL30869687 | 0.88 | ESR1 (0.33) | ESR1ESR2KRASKCNH2MCHR1 | |
| SCHEMBL30869444 | 0.88 | ESR1 (0.33) | ESR1ESR2KRASKCNH2MCHR1 | |
| SCHEMBL30869520 | 0.82 | PIM1 (0.33) | ESR1ESR2KRASKCNH2MCHR1 | |
| SCHEMBL30869722 | 0.81 | ESR1 (0.37) | ESR1ESR2KCNH2MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070880-A1 | DYNAMIN ACTIVATORS | WALDEN BIOSCIENCES, INC. (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4583868-A2 | DYNAMIN ACTIVATORS | Walden Biosciences, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024054661-A2 | DYNAMIN ACTIVATORS | WALDEN BIOSCIENCES (US) | 2024-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070880-A1 | DYNAMIN ACTIVATORS | DNM1, DNM1L, DNM2 | ESR1 3546/4885ESR2 2838/4885KRAS 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.